C1 esterase inhibitor (human) clinical trials
Also written CINRYZE and Berinert.
How each study uses C1 esterase inhibitor (human) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the C1 esterase inhibitor (human) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Oct 2008 · Cinryze · BLA 125267 (FDA, Purple Book)
- European Union
- 15 Jun 2011 · Cinryze · EMEA/H/C/001207 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 6
Shire (7) · Pharming Technologies B.V. (4) · Cedars-Sinai Medical Center (1) · Technical University of Munich (1) · GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Leiden University Medical Center (1) · University of Wisconsin, Madison (1)
Often tested with
Tested in the same studies.
Complement C1 Inhibitor Protein (4) · Conestat alfa (4) · Hyaluronidase (human recombinant) (2) · Icatibant (1)
Studies
Open first, then newest update. How each study uses C1 esterase inhibitor (human) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)RecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06919003Written as BerinertHow we know
- Berinert (C1INH) vs Placebo for DGF/IRICompletedPhase 1/2Cedars-Sinai Medical CenterNCT04696146Written as BerinertHow we know
- Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced AngioedemaCompletedPhase 3Technical University of MunichNCT01843530Written as BerinertHow we know
- Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).CompletedPhase 2GCS Ramsay Santé pour l'Enseignement et la RechercheNCT05010876Written as C1 Inhibitor HumanHow we know
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain InjuryStatus unknownPhase 2Leiden University Medical CenterNCT04489160Written as C1 Inhibitor, HumanHow we know
- A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human HyaluronidaseCompletedPhase 2ShireNCT01426763Written as CINRYZE with rHuPH20How we know
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE AdministrationCompletedPhase 2ShireNCT01095497Written as CINRYZEHow we know
- A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedPhase 4ShireNCT00914966Written as C1 inhibitor (human) [C1 INH]How we know
- A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated RejectionCompletedPhase 2ShireNCT01147302Written as C1 Esterase Inhibitor (Human)How we know
- Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema AttacksCompletedPhase 2ShireNCT01756157Written as CINRYZE with rHuPH20How we know
- CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12CompletedPhase 2ShireNCT01095510Written as CINRYZEHow we know
- CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%Status unknownPhase 1University of Wisconsin, MadisonNCT02435732Written as CINRYZEHow we know
- A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney TransplantTerminatedPhase 3ShireNCT02547220Written as Cinryze®How we know
- A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedPhase 2Pharming Technologies B.V.NCT00851409Written as Recombinant Human C1 InhibitorHow we know
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedPhase 2Pharming Technologies B.V.NCT02247739Written as Recombinant human C1 inhibitorHow we know
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedPhase 2/3Pharming Technologies B.V.NCT00225147Written as Recombinant Human C1 InhibitorHow we know
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedPhase 3Pharming Technologies B.V.NCT00262301Written as recombinant human C1 inhibitorHow we know
Given beside what is tested · 1 — C1 esterase inhibitor (human) is usual care or a partner of the new treatment
Codes
What other systems call C1 esterase inhibitor (human) · ClinicalTrials.gg INT004496
- UNII (FDA) 6KIC4BB60GHUMAN C1-ESTERASE INHIBITORConfirmed FDA, Wikidata
- RxNorm 809864Confirmed FDA, Wikidata
- Wikidata Q22075742C1 esterase inhibitor (human)Confirmed FDA, Wikidata
- DrugBank DB06404One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6KIC4BB60G | HUMAN C1-ESTERASE INHIBITOR | Confirmed FDA, Wikidata |
| RxNorm | 809864 | — | Confirmed FDA, Wikidata |
| Wikidata | Q22075742 | C1 esterase inhibitor (human) | Confirmed FDA, Wikidata |
| DrugBank | DB06404 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.